Lanchi Ventures Leads $42M Series A for Allink Biotherapeutics' Antibody and ADC Pipeline Development

Allink Biotherapeutics, a clinical-stage biotechnology company specializing in next-generation bispecific antibodies and antibody-drug conjugates (ADC) therapeutics, has announced the successful completion of a $42 million Series A financing round. This funding round was led by Lanchi Ventures, a global early-stage technology investor, with additional participation from Yuanbio Venture Capital, Legend Capital, and C&D Emerging Industry Equity Investment. Existing shareholders Gaorong Ventures and Med-Fine Capital also contributed to the round.

Dr. Hui Feng, Founder and CEO of AllinkBio, expressed gratitude for the support from existing shareholders and welcomed new investors who recognize the company's scientific potential and its ability to translate scientific research into clinical applications. The funds raised in this round will be used to accelerate the development of AllinkBio's diverse pipeline, which includes next-generation ADCs and bispecific antibodies targeting oncology and immunology diseases. Dr. Feng highlighted the company's progress from leading asset PCC to clinical development within a year of its inception, emphasizing the achievement as a significant milestone.

Lanchi Ventures, in their comments, praised AllinkBio's rapid progress in advancing its lead program from preclinical to clinical stages, underlining the company's strong competitiveness in the field. They also noted the innovative approach to ADC development as a promising opportunity in targeted oncology therapeutics.

The Series A financing will be allocated to several key areas: advancing the global clinical development of lead candidates ALK201 and ALK202 through Phase I studies in Australia, the United States, and China; expanding the current portfolio with the development of new assets in oncology and immunology; and further developing the company's bispecific antibody and ADC technology platform. Additionally, the funds will support AllinkBio's global footprint expansion as the company aims to achieve worldwide prominence.

This round of financing marks a pivotal moment in AllinkBio's growth journey, providing the necessary resources to accelerate both product and corporate development. With a focus on innovative therapeutics, the company aims to address significant unmet medical needs in the oncology and immunology sectors.

Founded in 2023, AllinkBio leverages its proprietary platforms in bispecific antibodies and ADCs to create a diverse pipeline of First-in-Class and Best-in-Class therapeutics. The company is committed to developing new drugs that can shift treatment paradigms for patients with critical medical needs globally.

Lanchi Ventures, a leading early-stage venture capital firm, has a long history of investing in technological innovations aimed at creating sustainable impact. With offices in Singapore, Hong Kong, and Beijing, Lanchi Ventures manages over $2 billion in capital and has invested in over 200 companies. Recognized by industry leaders such as Forbes, Fortune, and Preqin, the firm continues to support entrepreneurs across various sectors, including biotechnology.

AllinkBio's new financial backing and robust R&D capabilities position it for significant growth, paving the way for advancements in its product pipeline and corporate development. The company's progress underscores its potential to bring innovative therapeutics to the market, addressing the needs of patients with serious medical conditions.